263 related articles for article (PubMed ID: 28402937)
1. Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.
Langhammer S; Scheerer J
Oncotarget; 2017 Jun; 8(26):43555-43570. PubMed ID: 28402937
[TBL] [Abstract][Full Text] [Related]
2.
Hayashi T; Desmeules P; Smith RS; Drilon A; Somwar R; Ladanyi M
Clin Cancer Res; 2018 Mar; 24(6):1436-1447. PubMed ID: 29127119
[No Abstract] [Full Text] [Related]
3. MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer.
Li H; Lin PH; Gupta P; Li X; Zhao SL; Zhou X; Li Z; Wei S; Xu L; Han R; Lu J; Tan T; Yang DH; Chen ZS; Pawlik TM; Merritt RE; Ma J
Mol Cancer; 2021 Sep; 20(1):118. PubMed ID: 34521423
[TBL] [Abstract][Full Text] [Related]
4. Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts.
Gürgen D; Conrad T; Becker M; Sebens S; Röcken C; Hoffmann J; Langhammer S
Commun Biol; 2022 Jan; 5(1):59. PubMed ID: 35039644
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
Puri S; Shafique M; Gray JE
Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
[TBL] [Abstract][Full Text] [Related]
6. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling.
Baty F; Joerger M; Früh M; Klingbiel D; Zappa F; Brutsche M
J Transl Med; 2017 Mar; 15(1):66. PubMed ID: 28359318
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptors promote NSCLC progression by modulating the membrane receptor signaling network: a systems biology perspective.
Gao X; Cai Y; Wang Z; He W; Cao S; Xu R; Chen H
J Transl Med; 2019 Sep; 17(1):308. PubMed ID: 31511014
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Harichand-Herdt S; Ramalingam SS
Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
[TBL] [Abstract][Full Text] [Related]
9. Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.
Mazzaschi G; Leonetti A; Minari R; Gnetti L; Quaini F; Tiseo M; Facchinetti F
Curr Treat Options Oncol; 2021 Sep; 22(11):96. PubMed ID: 34524570
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
11. FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway.
Sun CC; Zhu W; Li SJ; Hu W; Zhang J; Zhuo Y; Zhang H; Wang J; Zhang Y; Huang SX; He QQ; Li DJ
Genome Med; 2020 Sep; 12(1):77. PubMed ID: 32878637
[TBL] [Abstract][Full Text] [Related]
12. [Research Advances of Ang-2 in Non-small Cell Lung Cancer].
Hua X; Zhu X
Zhongguo Fei Ai Za Zhi; 2018 Nov; 21(11):868-874. PubMed ID: 30454550
[TBL] [Abstract][Full Text] [Related]
13. A circular network of coregulated sphingolipids dictates lung cancer growth and progression.
Meng Q; Hu X; Zhao X; Kong X; Meng YM; Chen Y; Su L; Jiang X; Qiu X; Huang C; Liu C; Wang M; Wong PP
EBioMedicine; 2021 Apr; 66():103301. PubMed ID: 33813137
[TBL] [Abstract][Full Text] [Related]
14. Abandoning the Notion of Non-Small Cell Lung Cancer.
Relli V; Trerotola M; Guerra E; Alberti S
Trends Mol Med; 2019 Jul; 25(7):585-594. PubMed ID: 31155338
[TBL] [Abstract][Full Text] [Related]
15. Sulforaphane suppresses EMT and metastasis in human lung cancer through miR-616-5p-mediated GSK3β/β-catenin signaling pathways.
Wang DX; Zou YJ; Zhuang XB; Chen SX; Lin Y; Li WL; Lin JJ; Lin ZQ
Acta Pharmacol Sin; 2017 Feb; 38(2):241-251. PubMed ID: 27890917
[TBL] [Abstract][Full Text] [Related]
16. Emerging targets in advanced non-small-cell lung cancer.
Valentino F; Borra G; Allione P; Rossi L
Future Oncol; 2018 Jun; 14(13s):61-72. PubMed ID: 29989453
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
18. LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway.
He Y; Jiang X; Duan L; Xiong Q; Yuan Y; Liu P; Jiang L; Shen Q; Zhao S; Yang C; Chen Y
Mol Cancer; 2021 Dec; 20(1):156. PubMed ID: 34856993
[TBL] [Abstract][Full Text] [Related]
19. Elevation of EIF4G1 promotes non-small cell lung cancer progression by activating mTOR signalling.
Lu Y; Yu S; Wang G; Ma Z; Fu X; Cao Y; Li Q; Xu Z
J Cell Mol Med; 2021 Mar; 25(6):2994-3005. PubMed ID: 33523588
[TBL] [Abstract][Full Text] [Related]
20. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer.
Singh S; Trevino J; Bora-Singhal N; Coppola D; Haura E; Altiok S; Chellappan SP
Mol Cancer; 2012 Sep; 11():73. PubMed ID: 23009336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
